138356-55-5Relevant academic research and scientific papers
N-[2-(m-methoxyphenyl)ethyl]-N-ethyl-2-(1-pyrrolidinyl)ethylamine (UMB 116) is a novel antagonist for cocaine-induced effects
Daniels, AnTawan,Ayala, Erika,Chen, Weibin,Coop, Andrew,Matsumoto, Rae R.
, p. 61 - 68 (2006)
Previous research has shown that σ receptors participate in the actions of cocaine in the body. This has led to investigations of the use of novel agents such as BD1008, BD1067 and YZ-011 as cocaine antagonists. In the present study, three novel analogs (UMB115, UMB116, UMB117), representing composites of these earlier compounds, were evaluated in receptor binding and behavioral studies. In the receptor binding studies, the compounds were shown to have high affinity for σ receptors and much lower affinities for non-σ sites. For the behavioral experiments, Swiss Webster mice were pre-treated with saline or one of the novel compounds (0.1-10 mg/kg), followed 15 min later by a convulsive (60 mg/kg), lethal (125 mg/kg), or locomotor stimulatory (10 mg/kg) dose of cocaine. The results showed that UMB115, UMB116 and UMB117 significantly (P 0.05) inhibited cocaine-induced convulsions when administered as a pre-treatment to cocaine. Cocaine-induced lethality was significantly attenuated by UMB116 (P 0.05), but not by UMB115 and UMB117. All three compounds significantly (P 0.05) altered the locomotor stimulatory effects of cocaine, with UMB115 and UMB116 exhibiting attenuating actions. Together, the studies suggest UMB116 as a novel cocaine antagonist.
Synthesis, characterization, and biological evaluation of a novel class of N-(arylethyl)-N-alkyl-2-(1-pyrrolidinyl)ethylamines: Structural requirements and binding affinity at the σ receptor
De Costa,Radesca,Di Paolo,Bowen
, p. 38 - 47 (2007/10/02)
By synthesizing and testing a part-structure, N-[2-(3,4- dichlorophenyl)ethyl]-N-methyl-2-(1-pyrrolidinyl)ethylamine (3), derived from our previously reported high affinity σ receptor ligands (1S,2R)-(-)-N-[2- (3,4-dichlorophenyl)-ethyl]-N-methyl-2-(1-pyrrolidinyl)cyclohexylamine [(-)- 2] and (+)-2, we have identified a novel class of superpotent (subnanomolar affinity) σ ligands specific for the σ receptor labeled by [3H]-(+)-3-PPP. When 3 was tested for its capacity to displace [3H]-(+)-3-PPP from guinea pig brain membranes, it exhibited a K(i) of 0.34 nM, which is better than either of its parent compounds (-)-2 (K(i) = 1.3 nM) and (+)-2 (K(i) = 6.0 nM). Other compounds related to 3 such as N-[2-(3,4-dichlorophenyl)ethyl]-N- methyl-2-(1-homopiperidinyl)ethylamine (19) exhibited K(i) = 0.17 nM ([3H]- (+)-3-PPP). The determinants for high σ receptor affinity of 3 were examined by manipulation of this structure in a number of different ways. The high efficacy of these compounds for the σ receptor, their relative chemical simplicity and ease of synthesis, and their high degree of selectivity identifies N-[2-(3,4-dichlorophenyl)ethyl]-N-methyl-2-(1- pyrrolidinyl)ethylamine (3) and related compounds as a highly promising base for determination of the functional role of σ receptors as well as the development of novel therapeutic agents.
